Brain Metastases, Radiotherapy Side Effect
Conditions
Keywords
Brain metastases, Radiotherapy, Stereotactic Body Radiotherapy, Radiosurgery, Radionecrosis, Local Control, Safety profile, Radiomics
Brief summary
The study design concerns all patients diagnosed witha singular brain metastasis who underwent stereotactic radiosurgery/radiotherapy between January 2010 and December 2022
Detailed description
The study will include patients of both sexes diagnosed with single brain metastases who underwent radiosurgical/stereotactic treatment. Attention will be paid to data related to local control, potential recurrence, and/or radionecrosis. Once a sufficient number of treated patients is reached, the feasibility of a radiomic feature analysis will be assessed in order to identify potential correlations and/or predictive values for treatment response or radionecrosis. If the sample size is adequate, participating centers will be asked to share pre- and post-RT MRI (brain MRI with contrast using thin slices) and treatment volumes for radiomic evaluation.
Interventions
RADIATIONStereotactic Body Radiotherapy/Radiosurgery
Stereotactic Body Radiotherapy/Radiosurgery
Sponsors
Gemelli Molise Hospital
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥ 18 years * Treatment with SRS/SRT techniques for a single secondary brain lesion * Availability of pre-RT brain MRI with contrast (1mm slice thickness) * Availability of CT simulation imaging for treatment * Availability of relevant clinical data in the medical record for the study's objectives * Follow-up of at least 6 months after the completion of SRS or SRT * Follow-up evaluation through brain MRI
Exclusion criteria
* Age under 18 years * Lack of clinical/radiological data for the patient * Unavailability of the required imaging * Previous whole-brain radiotherapy treatment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Toxicity profile | due to the retrospective nature of the study, we did not have specific time points.We will evaluate the possible onset of toxicity events from the last day of treatment up to 18 months from the treatment | The toxicity profile of the treatment will be assessed according to the Common Terminology Criteria for Adverse Events (CTCAE) of the National Cancer Institute. |
| Local control | We will evaluate Lc at one, two, and five years from the treatment | It will be Calculated 'per lesion,' and it is defined as the time interval between irradiation and the onset of disease recurrence at the site of the treated area |
Countries
Italy
Outcome results
None listed